Sanjay Godhwani, MD
Rheumatology · Wading River, NYNPI 1174783567
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $378,158 of the $472,075 with a category attached, or 80.1%. 35 manufacturers reported payments, led by Amgen at 45.8% of the total. Among rheumatology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,573 payments — averaging $300.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$216K
- AbbVie$163K
- AstraZeneca$36K
- Bristol Myers Squibb$15K
- Novartis$11K
- Pfizer$11K
- plus $20K from 29 others
What the payments were for
- Consulting fees$19,9654%
- Speaking & faculty fees$378,15880%
- Travel & lodging$31,6577%
- Food & beverage$41,4819%
- Education$8140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 490 | $216,181 |
| AbbVie | 380 | $162,803 |
| AstraZeneca | 49 | $35,572 |
| Bristol Myers Squibb | 34 | $14,625 |
| Novartis | 47 | $11,484 |
| Pfizer | 122 | $11,052 |
| Johnson & Johnson(2 entities) | 123 | $6,581 |
| Medexus Pharma, Inc. | 11 | $4,564 |
| UCB, Inc. | 41 | $1,851 |
| Mallinckrodt Hospital Products Inc. | 26 | $1,320 |
| E.r. Squibb & Sons, L.L.C. | 52 | $1,161 |
| GSK | 31 | $667 |
| Lilly USA, LLC | 31 | $609 |
| ANI Pharmaceuticals, Inc. | 22 | $559 |
| Mallinckrodt Enterprises LLC | 16 | $532 |
| Regeneron Healthcare Solutions, Inc. | 7 | $416 |
| Boehringer Ingelheim | 14 | $339 |
| Radius Health, Inc. | 23 | $319 |
| Genentech USA, Inc. | 16 | $306 |
| Organon | 9 | $185 |
| Merck | 4 | $175 |
| Pacira Therapeutics, Inc. | 3 | $172 |
| Aurinia Pharma U.S., Inc. | 3 | $142 |
| Octapharma USA, Inc. | 2 | $118 |
| Sanofi | 4 | $78 |
| Hikma Pharmaceuticals USA | 3 | $57 |
| Kyowa Kirin, Inc. | 2 | $53 |
| Daiichi Sankyo Inc. | 1 | $30 |
| Vertex | 1 | $20 |
| Antares Pharma, Inc. | 1 | $20 |
| Sandoz | 1 | $19 |
| Tonix Medicines, Inc. | 1 | $18 |
| Arbor Pharmaceuticals, Inc. | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Ultragenyx Pharmaceutical Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$472,075 in reported general payments places this provider in the 95th percentile of 541 rheumatology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RinvoqUpadacitinib | 86 | $702,634 |
| Humira(Cf) PenAdalimumab | 65 | $612,289 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 13 | $450,109 |
| Enbrel SureclickEtanercept | 50 | $377,822 |
| Skyrizi PenRisankizumab-Rzaa | 11 | $217,699 |
| Diclofenac Potassium | 28 | $196,311 |
| Xeljanz XrTofacitinib Citrate | 22 | $175,700 |
| Diclofenac Sodium | 67 | $130,746 |
| MeloxicamMeloxicam, Submicronized | 20 | $67,437 |
| KineretAnakinra | 12 | $66,887 |
| OtezlaApremilast | 11 | $58,431 |
| RayosPrednisone | 11 | $57,608 |
| Naproxen-Esomeprazole MagNaproxen/Esomeprazole Mag | 11 | $43,231 |
| TymlosAbaloparatide | 12 | $31,228 |
| Leflunomide | 237 | $22,895 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $162,803 | $702,63486 claims |
| AmgenOtezla, Rayos | $216,181 | $116,04022 claims |
| Radius Health, Inc.Tymlos | $319 | $31,22812 claims |
| Boehringer IngelheimTradjenta | $339 | $6,19712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 541 rheumatology providers in New York.
Other rheumatology in Wading River
- Laurie GlimcherNew York$3.9M
- Grace WrightNew York$3M
- Kostas BotsoglouCheektowaga$2.6M
- Sergio SchwartzmanNew York$2.5M
- Allan GibofskyNew York$1.9M
- Petros EfthimiouNew York$791K
- Richard FurieNew Hyde Park$746K
- Barry GruberBabylon$742K
- Olga PetrynaNew York$509K
- Danielle PeterselNew York$461K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.